{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:59:55Z","timestamp":1772585995832,"version":"3.50.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> Vaccination is one of the most convenient and safe preventive care measures available for children. The Pentavalent vaccine which protects against five major infections including diphtheria, tetanus, pertussis, hepatitis B(HepB) and <jats:italic>Haemophilus influenzae type b<\/jats:italic>(<jats:italic>Hib<\/jats:italic>) was added to the Iranian national immunization program in November 2014. This study aimed to determine the Pentavalent vaccine adverse events and immunogenicity in an Iranian children population in Sari, northern Iran.<\/jats:p><jats:p><jats:bold>Method:<\/jats:bold> In this descriptive-analytical study, children who were vaccinated with three doses of the Pentavalent vaccine were studied. Two venous blood samples were obtained before the first dose and 4 weeks following the last booster dose. Possible local and systemic complications of the vaccine were recorded until 7 days following vaccination. Antibody titers were measured by quantitative ELISA kits and geometric mean titer(GMT) was calculated for each vaccine component before and after 3 doses of vaccine. Statistical analysis was performed by SPSS 20.0 software and Chi-square and Fisher's exact tests were used for analysis.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Immunogenicity of the Pentavalent vaccine for tetanus was 100%(GMT:2.52 Eu\/mL, 95%CI: 2.22\u20132.88), <jats:italic>Hib<\/jats:italic> 98.7%(GMT:2.44 Eu\/mL, 95%CI: 2.06\u20132.89), HepB 98.7%(GMT:153.54 Eu\/mL, 95%CI: 133.73\u2013176.29), diphtheria 93.1%(GMT:0.43 Eu\/mL, 95%CI:0.37\u20130.51) and pertussis were 63.7% (GMT:19.44 Eu\/mL, 95%CI:16.42\u201323.03). The most common systemic complication after vaccination was fever. Also, one infant cried for more than 3 hours after the second dose. Other serious side effects were not observed.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The Pentavalent vaccine used in Iran can cause adequate antibody response against diphtheria, tetanus, pertussis, <jats:italic>Hib<\/jats:italic> and hepatitis B in most cases with minimal side effects. The immunogenicity of this vaccine is significantly lower for pertussis. In this study, no severe complication leading to contraindication to subsequent injections was reported. So, the present policy in replacing triple DTP vaccine with Pentavalent vaccine should be continued in Iran.<\/jats:p>","DOI":"10.3389\/fped.2021.716779","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T17:26:17Z","timestamp":1633109177000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunogenicity and Complications of the Pentavalent Vaccine in Iranian Children"],"prefix":"10.3389","volume":"9","author":[{"given":"Mina","family":"Ekrami Noghabi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Jafar","family":"Saffar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaghayegh","family":"Rezai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Saffar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiva","family":"Saffar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Hosseinzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliasghar","family":"Nadi Ghara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Sadegh","family":"Rezai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12865-017-0226-8","article-title":"Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran","volume":"18","author":"Karami","year":"2017","journal-title":"BMC Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijid.2016.02.015","article-title":"Comparison of the immunogenicity and safety of pentavalent vaccine Quinvaxem in a compact prefilled auto-disabled (cPAD) injection system versus single-dose vials in healthy infants: a phase 3, open-label, randomized, parallel-group, non-inferiority study","volume":"46","author":"Capeding","year":"2016","journal-title":"Int J Infect Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.tmaid.2014.04.004","article-title":"The 2014 FIFA world cup: communicable disease risks and advice for visitors to Brazil\u2013a review from the Latin American society for travel medicine (SLAMVI)","volume":"12","author":"Gallego","year":"2014","journal-title":"Travel Med Infect Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.pedhc.2007.09.004","article-title":"Societal impact of combination vaccines: experiences of physicians, nurses, and parents","volume":"22","author":"Koslap-Petraco","year":"2008","journal-title":"J Pediatr Health Care."},{"key":"B5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/01.inf.0000222413.47344.23","article-title":"The use of combination vaccines has improved timeliness of vaccination in children","volume":"25","author":"Kalies","year":"2006","journal-title":"Pediatr Infect Dis J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1016\/j.vaccine.2019.06.067","article-title":"Immunogenicity and safety of a liquid pentavalent (DTwP-Hb-Hib) combination vaccine manufactured by human biologicals institute in 6\u20138 weeks old healthy infants: a phase III, randomized, single blind, non-inferiority study","volume":"37","author":"Susarla","year":"2019","journal-title":"Vaccine."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e1716","DOI":"10.1542\/peds.2012-3836","article-title":"Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers","volume":"131","author":"Klein","year":"2013","journal-title":"Pediatrics."},{"key":"B8","doi-asserted-by":"publisher","first-page":"100321","DOI":"10.1016\/j.conctc.2019.100321","article-title":"Clinical study of safety and immunogenicity of pentavalent DTP-HB-Hib vaccine administered by disposable-syringe jet injector in India","volume":"14","author":"Bavdekar","year":"2019","journal-title":"Contemp Clin Trials Commun."},{"key":"B9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3389\/fped.2020.613433","article-title":"Routine pediatric vaccination in Pakistan during COVID-19: how can healthcare professionals help?","volume":"8","author":"Khan","year":"2020","journal-title":"Front Pediatr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.vaccine.2012.11.038","article-title":"Antibody persistence of two pentavalent DTwP\u2013HB\u2013Hib vaccines to the age of 15\u201318 months, and response to the booster dose of quadrivalent DTwP\u2013Hib vaccine","volume":"31","author":"Sharma","year":"2013","journal-title":"Vaccine."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1016\/j.vaccine.2017.05.043","article-title":"Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib)","volume":"35","author":"Martin\u00f3n-Torres","year":"2017","journal-title":"Vaccine."},{"key":"B12","first-page":"753","article-title":"Immunogenicity and safety of quinvaxem(diphteria,tetanus, whole-cell pertussis,hepatitis B and haemophilus influnzae type B vaccine) given to Vietnames infant at 2 to 4 month of age","volume":"46","author":"Huu","year":"2015","journal-title":"Southeast Asian J Trop Med Public Health."},{"key":"B13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/21645515.2018.1536588","article-title":"Immunogenicity and safety of a combined DTPa-IPV\/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study","volume":"15","author":"Kim","year":"2019","journal-title":"Hum Vaccin Immunother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12887-015-0525-2","article-title":"The immunogenicity, safety, and consistency of an Indonesia combined DTP-HB-Hib vaccine in expanded program on immunization schedule","volume":"15","author":"Rusmil","year":"2015","journal-title":"BMC Pediatr."},{"key":"B15","doi-asserted-by":"publisher","first-page":"7023","DOI":"10.5812\/archcid.59344","article-title":"Study of serologic response rate to pertussis after administration of the third dose of pentavalent vaccine in children 12 months old in Karaj City, Iran","volume":"6","author":"Arjmand","year":"2018","journal-title":"Int J Pediatr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1093\/cid\/ciz143","article-title":"Seroprotection at different levels of the healthcare system after routine vaccination with diphtheria-tetanus-pertussis whole cell\u2013hepatitis B\u2013haemophilus influenzae type B in lao people's democratic republic","volume":"69","author":"Hefele","year":"2019","journal-title":"Clin Infect Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/21645515.2018.1549449","article-title":"Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States","volume":"15","author":"Klein","year":"2019","journal-title":"Hum Vaccin Immunother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3346\/jkms.2016.31.9.1383","article-title":"The Immunogenicity and safety of a combined DTaP-IPV\/\/Hib Vaccine compared with individual DTaP-IPV and Hib (PRP~T) Vaccines: a Randomized Clinical Trial in South Korean Infants","volume":"31","author":"Kang","year":"2016","journal-title":"J Korean Med Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1080\/21645515.2016.1239670","article-title":"Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and haemophilus influenzae type b conjugate vaccine (DTPa-IPV\/Hib) administered in Chinese infants","volume":"13","author":"Li","year":"2017","journal-title":"Hum Vaccin Immunother."},{"key":"B20","first-page":"1","article-title":"Comparison of complications of pentavalent and DTP vaccination in infants aged 2-6 months in Anzali, Iran","volume":"7","author":"Sharafi","year":"2016","journal-title":"Iran J Neonatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1080\/21645515.2015.1100779","article-title":"Safety, immune lot-to-lot consistency and non-inferiority of a fully liquid pentavalent DTwp-HepB-Hib vaccine in healthy Indian toddlers and infants","volume":"12","author":"Gandhi","year":"2016","journal-title":"Hum Vaccin Immunother."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.716779\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T17:26:21Z","timestamp":1633109181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.716779\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":21,"alternative-id":["10.3389\/fped.2021.716779"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.716779","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]},"article-number":"716779"}}